3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasm Metastasis
9
Colorectal Neoplasms
7
Rectal Neoplasms
5
Colorectal Cancer Metastatic
5
Ovarian Neoplasms
4
Neoplasms
4
Lung Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Melanoma
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 2
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Macular Degeneration
1
Interventions
brolucizumab
1
aflibercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Macular Degeneration
×
aflibercept
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts